Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy
2024 · Nature · 280 citations
https://doi.org/10.1038/s41586-024-07205-6
J
John E. Knox
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
126
Papers
1.9K
Citations
23
h-index
34
i10-index
John E. Knox is an academic researcher from Revolution Medicines (United States). The author has contributed to research in topics: Cancer, Hypoxia, and Metabolism & Cancer Research and Treatments & ATP Synthase and ATPases Research. The author has an h-index of 23, co-authored 108 publications.
ORCID: 0009-0006-6246-5198Papers by this author
worksTranslational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
2024 · Cancer Discovery · 241 citations
https://doi.org/10.1158/2159-8290.cd-24-0027
Finding New Medicines for Flaviviral Targets
2006 · Novartis Foundation symposium · 52 citations
https://doi.org/10.1002/0470058005.ch8
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
2025 · Journal of Medicinal Chemistry · 37 citations
https://doi.org/10.1021/acs.jmedchem.4c02314
A neomorphic protein interface catalyzes covalent inhibition of RAS <sup>G12D</sup> aspartic acid in tumors
2025 · Science · 22 citations
https://doi.org/10.1126/science.ads0239
The “three body solution”: Structural insights into molecular glues
2025 · Current Opinion in Structural Biology · 10 citations
https://doi.org/10.1016/j.sbi.2025.103007
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat